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C.  Practices at risk of inappropriateness in prevention of MRONJ and 
good practices
Very recently, some Italian experts of the SIPMO ONJ board have defined 
in an open-access peer-reviewed document the new paradigms by SIPMO 
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on preventive dental management in patients at risk of MRONJ, prior to and 
during/after the administration of the aforementioned ONJ-related drugs 
[1]. The MRONJ Italian Consensus has confirmed the principles declared by 
the SIPMO ONJ board in terms of prevention. Briefly, they believe that, for 
reducing the risk of MRONJ, key figures are prescribers, dentists and oral 
hygienists by applying correct protocols of 1) primary prevention for both 
pre-treatment and in-treatment patients, and 2) secondary prevention (i.e. 
early diagnosis of MRONJ). 
1) Primary prevention for MRONJ mainly means elimination/reduction of 
oral and dental risk factors, it is targeted at restoring and/or maintain-
ing good oral health and reducing the risk of an onset of pathological 
conditions or any other negative event. This approach has the greatest 
impact when aimed at protecting constantly the oral health of patient 
at risk of MRONJ.
 Initially, about fifteen years ago, MRONJ (at that time labeled BRONJ) has 
been thought to be associated to dental extraction in patients already 
being treated with bisphosphonates. More recently, the presence of infec-
tion at dental-periodontal and peri-implant locations has been underlined 
as being one of the main local risk factors of developing MRONJ, often 
being the main reason of surgical procedures of dental extraction or 
implant removal. It is advisable to consult the full text by SIPMO ONJ 
board for the division by risk categories, for a complete listing of systemic 
and local risk factors. 
 A new emerging aspect is that primary prevention should be performed 
not only prior to taking the ONJ-related drugs, but also during and after 
the treatment with those drugs, in order to eliminate any infective out-
breaks of MRONJ. It is the responsibility of the dentist to accurately assess 
risk factors leading to the development of MRONJ and suggest a strategy 
for removing these factors. The dentist must also stress the importance 
of maintaining e!ective dental hygiene (together with dental hygienist), 
including regular check-ups, for the patient. Both are necessary for main-
taining oral health, reducing the outbreak of MRONJ, and/or detecting 
possible signs of the early symptoms of this disease.
 Finally, dental procedures for the patient (both cancer and non-cancer) in 
pre-treatment and in-treatment phases can be divided in invasive and non- 
invasive ones, all indicated in these patients when related to the control 
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of local risk factors. Of great assistance in this regard is the use of leaf-
lets, such as those which can be free downloaded, https://www.unipa.it/
dipartimenti/di.chir.on.s./. content/documenti/ONJ-Leaflet-_SIPMO-by-
Di-Fede-Campisi20-02-17.pdf. The app DoctOral® provides an open- 
access consultation of guided paths and recommendations regarding 
the dental management of patients at risk of MRONJ; it is free available 
both for Android, https://play.google.com/store/apps/details?id=com.
olgadifede.olgapp&hl=it and iOS system [2], https://itunes.apple.com/
it/app/doc toral/id1232326837?mt=8. 
2) Secondary prevention or early diagnosis is the second pillar in the strat-
egy against MRONJ, since we know that the earlier the MRONJ stage 
is, its prognosis will be better. With respect to the diagnostic work-up, 
the main problem is the possible under-diagnosing of MRONJ cases 
without bone exposure. A recent multicenter study [3] has demon-
strated that the use of the traditional AAOMS [4,5] and ASBMR case 
definition [6] induces clinicians up to a quarter of undiagnosed BRONJ 
cases. Thus, in order to avoid any underestimation of MRONJ, care 
should be taken with respect to the definition adopted and to the use 
of the imaging studies in cancer and osteometabolic patients, who 
are already receiving MRONJ-associated therapies in combination 
or alone [7].
Practices at risk of inappropriateness 
#1 keeping teeth with endodontic and/or periodontal diseases at uncertain 
prognosis only for avoiding, in patients at risk of MRONJ, extractive inva-
sive procedures.
#2 extracting, only for preventive purposes, teeth in partial or total inclusion 
in patients pre-treatment with drugs at risk of ONJ.
#3 scheduling in cancer patients the first dental check-up only after diagnosis 
of bone metastases. 
#4 omitting in osteometabolic patients dental check-ups for oral health status 
assessment and relative preventive dentistry actions.
#5 omitting periodic dental check-ups for edentulous patients or wearing 
removable prostheses, if they are at risk of MRONJ.
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#6 underestimating the usefulness of imaging performed for monitoring 
neoplastic status with respect to ONJ diagnosis. 
Good practices
#1 extract teeth with endodontic and/or periodontal diseases, in patients at 
risk of MRONJ, when conservative approach is not possible and a good 
prognosis is not guaranteed.
#2 maintain teeth in partial or total inclusion, if no signs and/or symptoms 
of inflammation/infection are presents (e.g. dysodontiasis, pericoronaritis, 
decay, periodontal disease, caries and /or root resorption of the second 
molar, mechanical trauma on the surrounding mucous membranes).
#3 schedule in cancer patients the first dental check-up as soon as possible, 
preferably during the tumour staging process in the pre-treatment phase.
#4 consider in osteometabolic patients a potential gradient of MRONJ risk 
according to 
a) Administration and duration of treatment with ONJ-related drugs 
[8–11] and 
b) Eventual presence of comorbidities and further medical therapies indi-
rectly associated; assess, during the prescription of the ONJ-associated 
drugs, the oral health status even by a questionnaire (bypassing the 
preliminary dental check-up); schedule semi-annual dental visits (the 
first within 6 months from the first assumption of anti-resorptive drugs). 
#5 schedule preventive dental check-ups even in patients at risk of MRONJ 
but edentulous with or without removable dentures, in order to intercept 
and correct any injury on the oral mucosa.
#6 consider useful, in cancer patients, the imaging investigations of II level 
(e.g. PET, bone scintigraphy) already performed for detecting early radi-
ological signs of MRONJ, especially before prescribing further specific 
imaging.
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D.  Practices at risk of inappropriateness in dental management and 
good practices for patients at risk of MRONJ
As before illustrated, the SIPMO ONJ board has defined in an open-access 
peer-reviewed shared protocols for dental management in patients at risk of 
MRONJ, prior to and during/after the administration of the aforementioned 
ONJ-related drugs [1]. The MRONJ Italian Consensus has adopted the prin-
ciples and good practices stated by the SIPMO ONJ board with respect to 
dental management. In particular, as follows, some hot points were here 
emphasized: implants in cancer and osteometabolic patients, antibiotic 
prophylaxis, healing for I vs II intention.
Practices at risk of inappropriateness 
#1 following an implant rehabilitation in cancer patients who have to take 
or are taking MRONJ-associated drugs.
#2 considering as contraindicated, in an absolute sense, implant rehabilitation 
in ostometabolic patients taking MRONJ-associated drugs.
#3 prescribing antibiotic prophylaxis before dental therapies as non-invasive 
for bone.
#4 practicing extractive procedures without removing, even if necessary, 
alveolar bone, and plan healing for second intention (especially with 
cortisone administration).
Good practices
#1 do not perform in cancer patients implant rehabilitation and plan non- 
surgical rehabilitation.
#2 practice in osteometabolic patients implant rehabilitation taking into 
account the cumulative dose of drug already taken, the periodontal status, 
any smoking, comorbidities and other drugs. Sharing with the patient a 
hypothetical medium-long term risk of MRONJ related to peri-implantitis 
and bone mini-cracks. Plan informed consent and six months follow-up.
#3 recommend always, in patients at MRONJ risk, antibiotic prophylaxis when 
surgical procedures involving dento-alveolar process or maxillary bones 
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are planned (e.g. extractions, periodontal/endodontic surgery, implants, 
pre-implant surgery).
#4 practice extractive or surgical procedures planning the healing for first 
intent with the clot maintenance.
Keywords: MRONJ, ONJ (osteonecrosis of the jaws), BRONJ (Bisphosphonate-Related 
Osteonecrosis of the Jaw), risk of inappropriateness, MRONJ Italian Consensus, SIPMO, SIdCO
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